Flush Free Niacin 2X Fact Sheet
Neil E. Levin, CCN, DANLA
Revised 8/7/07
SIZE/POTENCY: 90 Vcaps, 500 mg
LIKELY USERS: Those trying to maintain cholesterol already within a healthy range
KEY INGREDIENT(S): Inositol Hexanicotinate 640 mg
MAIN PRODUCT FEATURES: Inositol Hexanicotinate is a stable, non-flushing source of Niacin, a form of Vitamin B-3. This double strength formula provides 500 mg. of niacin (as nicotinic acid) per capsule, along with 135 mg. of inositol. The slow breakdown of this compound means that blood serum levels of niacin do not reach their maximum until about ten hours after taking this formula, normally avoiding niacin’s usual “flushing” effect. The “niacin flush”, a safe but uncomfortable brief redness, itching and feeling of warmth caused by larger doses of niacin stimulating the release of histamine in capillaries near the skin, should not normally occur with Flush Free Niacin.
Niacin’s actions include helping the body maintain a normal, healthy lipid profile. Niacin is utilized by the body as an essential nutrient for carbohydrate, alcohol and fat metabolism.
Niacin is also known to help maintain proper circulation of blood, especially peripheral circulation.
This is a vegetarian formula in a Vcap.
This formula contains twice the dose of our regular Flush Free Niacin formula.
OTHER IMPORTANT ISSUES: Many doctors prefer this form of niacin to time-release niacin formulas, due to problems with niacin flushing and liver toxicity associated with the time-release forms.
Inositol is a substance found in grains and a component of lecithin, also known as phytate, which is used for healthy nerves and cell membranes. Inositol is also involved in fat metabolism.
AMOUNT TO USE: One or more Vcaps a day, preferably with meals.
CONSIDER TAKING WITH: B-complex vitamins, garlic, fish oil, flax oil, olive oil, fiber, lecithin, plant sterols (phytosterols) and sterolins, Vitamin E (mixed tocopherols and tocotrienols), nuts, policosanols, chromium, Vitamin C, pantethine (a form of Vitamin B-5).
CAUTIONS: People using very high doses of niacin under a doctor’s supervision should be monitored for proper liver function and also take a B-Complex formula to avoid increasing their levels of homocysteine, a potentially harmful metabolite. Niacin should not be used by pregnant women, nursing mothers, people with stomach ulcers, diabetics or those with liver problems unless recommended under the supervision of a healthcare professional.
Please notify your physician about your supplement use if you are using ANY drugs!
REFERENCES
Ring EFJ, Porto LO, Bacon PA. Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome. J Int Med Res. 1981;9:393-400. O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol hexanicotinate (Hexopal®) in intermittent claudication: A controlled trial. Br J Clin Pract. 1988;42:377-383. Murphy R. The effect of inositol hexanicotinate (Hexopal) in patients with Raynaud's syndrome. Clin Trials J. 1985;22:521-529. Kiff RS. Does inositol hexanicotinate (Hexopal) influence intermittent claudication? Br J Clin Pract. 1988;42:141-145. Head A. Treatment of intermittent claudication with inositol nicotinate. Practitioner. 1986;230:49-54. Eur J Clin Pharmacol. 1979 Aug;16(1):11-5. Nocturnal inhibition of lipolysis in man by nicotinic acid and derivatives. Kruse W, Kruse W, Raetzer H, Heuck CC, Oster P, Schellenberg B, Schlierf G. PMID: 499296 [PubMed - indexed for MEDLINE] Welsh AL, Ede M. Inositol hexanicotinate for improved nicotinic acid therapy. Int Record Med. 1961;174:9-15. Hammerl H, Kraenzyl CH, Sudlar M. Metabolic studies for determination of the action mechanism of a ß-sympathometic. Wein Klin Woschenschr. 1968;80:269. Sommer H. Nicotinic acid levels in the blood and fibrinolysis under the influence of the hexanicotinic ester of m-inositol. Arzneim Forsch. 1975;15:1337. Dorner VG, Fischer FW. The influence of m-inositol hexanicotinate ester on the serum lipids and lipoproteins. Arzneim Forsch. 1961;11:110-113. El-Eneim AMA, Hafez YS, Salem H, Abdel M. The role of nicotinic acid and inositol hexanicotinate as anticholesterolemic and antilipemic agents. Nutr Reports Int. 1983;28:899-911. Mercier J, Gavend MR, Dessaigne S. Effect of inositol and its derivatives on hypercholesterolemic rabbits. Cong Union Therap Intern (Brussels). 1963;8:11. Kruse W, Kruse W, Raetzer H, et al. Nocturnal inhibition of lipolysis in man by nicotinic acid and derivatives. Eur J Clin Pharmacol. 1979;16:11-15. |
